Cargando…
Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta® from August 2020 to October 2021 in China
The proposed biosimilar candidate needs to demonstrate biosimilarity with reference products, and the quality target product profile and biosimilarity assessment criteria are prerequisite, which should be based on extensive characterization of the reference products. In this study, 13 lots of China-...
Autores principales: | Yao, Bing, Zhang, Di, Cao, Weirong, Yang, Gaoqiang, Li, Wenbin, Hui, Xiwu, Ouyang, Pingkai, Chen, Guoguang, Liu, Boning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078787/ https://www.ncbi.nlm.nih.gov/pubmed/35535043 http://dx.doi.org/10.1155/2022/7868391 |
Ejemplares similares
-
Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions
por: Ding, Huandi, et al.
Publicado: (2023) -
ADCC potency assay: increased standardization with modified lymphocytes
por: Bretaudeau, Laurent, et al.
Publicado: (2011) -
Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta® in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2021) -
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
por: Kim, Seokkyun, et al.
Publicado: (2017) -
Corrigendum: Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta(®) in Healthy Chinese Male Volunteers
por: Cui, Yingzi, et al.
Publicado: (2022)